Want to see FR:IPN full AI Analyst Report?
Top Page
Ipsen
(IPN)
Select Model
Select Model
Rating:65Neutral
Price Target:
€172.00
▲(8.59% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily supported by solid underlying financial performance (steady revenue growth, healthy margins, and manageable leverage), but is held back by margin compression and cash-flow volatility. Technicals add caution due to negative MACD and a largely trendless setup around key moving averages, while valuation is restrained by a ~27 P/E and sub-1% dividend yield.
Positive Factors
Revenue Growth
Consistent multi-year topline expansion, including a notable 2025 step-up, indicates durable demand across Ipsen's specialty franchises. Sustained revenue growth improves scale economics, supports continued R&D and launches, and lowers execution risk for medium-term commercialization plans.
Negative Factors
Margin Compression
Sustained decline in profitability versus prior years points to structural cost pressures, adverse product mix, or increased competition. Lower margins reduce internal funding for growth, weaken return on incremental capital, and may limit ability to absorb pricing or reimbursement shocks over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent multi-year topline expansion, including a notable 2025 step-up, indicates durable demand across Ipsen's specialty franchises. Sustained revenue growth improves scale economics, supports continued R&D and launches, and lowers execution risk for medium-term commercialization plans.
Read all positive factors
Ipsen (IPN) vs. iShares MSCI France ETF (EWQ)
Market Cap
€13.51B
Dividend Yield0.98%
Average Volume (3M)64.26K
Price to Earnings (P/E)26.4
Beta (1Y)0.56
Revenue Growth13.63%
EPS Growth14.45%
CountryFR
Employees5,535
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)6.20
Shares Outstanding83,814,530
10 Day Avg. Volume52,964
30 Day Avg. Volume64,259
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€177.50Price Target Upside12.06% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)14.3
Revenue Forecast (FY)€4.45B
Ipsen Business Overview & Revenue Model
Company Description
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; ...
How the Company Makes Money
Ipsen makes money primarily by selling prescription medicines through its Specialty Care business. Revenue is largely generated from product sales of its marketed drugs to wholesalers, hospitals, pharmacies, and healthcare providers (depending on ...
Ipsen Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.05B | 3.68B | 3.57B | 3.31B | 3.16B | 2.75B |
| Gross Profit | 2.73B | 2.59B | 2.96B | 2.74B | 2.63B | 2.31B |
| EBITDA | 1.49B | 1.10B | 1.16B | 1.14B | 1.13B | 1.06B |
| Net Income | 512.60M | 444.50M | 345.90M | 644.40M | 648.60M | 646.60M |
Balance Sheet | ||||||
| Total Assets | 7.46B | 6.94B | 6.44B | 6.32B | 5.61B | 4.99B |
| Cash, Cash Equivalents and Short-Term Investments | 1.97B | 1.53B | 679.20M | 528.40M | 1.17B | 814.70M |
| Total Debt | 963.20M | 867.10M | 426.80M | 462.90M | 771.60M | 786.60M |
| Total Liabilities | 2.75B | 2.60B | 2.26B | 2.50B | 2.27B | 2.25B |
| Stockholders Equity | 4.71B | 4.34B | 4.18B | 3.83B | 3.34B | 2.74B |
Cash Flow | ||||||
| Free Cash Flow | 1.23B | 1.03B | 133.00M | 749.70M | 700.30M | 453.90M |
| Operating Cash Flow | 1.30B | 1.14B | 915.50M | 865.90M | 953.20M | 871.80M |
| Investing Cash Flow | -557.50M | -615.20M | -676.60M | -1.07B | -458.60M | -332.00M |
| Financing Cash Flow | -227.70M | 298.40M | -100.00M | -458.40M | -146.00M | -400.30M |
Ipsen Technical Analysis
Positive
158.40
Price Trends
161.47
Positive
160.95
Positive
148.54
Positive
Market Momentum
0.42
Negative
53.84
Neutral
76.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IPN, the sentiment is Positive. The current price of 158.4 is below the 20-day moving average (MA) of 160.01, below the 50-day MA of 161.47, and above the 200-day MA of 148.54, indicating a bullish trend. The MACD of 0.42 indicates Negative momentum. The RSI at 53.84 is Neutral, neither overbought nor oversold. The STOCH value of 76.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:IPN.
Ipsen Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €13.51B | 26.35 | 10.36% | 1.01% | 13.63% | 14.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | €66.90M | -17.63 | 6.99% | ― | 9.51% | 73.33% | |
47 Neutral | €554.91M | -3.30 | -106.22% | ― | -27.19% | -117.39% | |
46 Neutral | €1.89B | -74.59 | 31.23% | ― | ― | ― | |
43 Neutral | €8.74B | -21.08 | -165.19% | ― | ― | ― | |
43 Neutral | €783.90M | -3.79 | -119.47% | ― | ― | 41.33% |
* General Sector Average
FR:IPN
Ipsen
163.40
49.11
42.97%
FR:ABVX
Abivax SA
101.80
36.40
55.66%
FR:DBV
DBV Technologies
2.50
0.85
51.21%
FR:NANO
Nanobiotix
38.04
30.12
380.30%
FR:VLA
Valneva
2.97
-0.96
-24.45%
FR:AB
AB Science SA
0.69
-0.57
-45.00%
Ipsen Corporate Events
Ipsen Reports Share Buybacks on Euronext Paris in Late July 2026
Aug 3, 2026
Ipsen disclosed that it conducted share buyback transactions between 27 July and 31 July 2026 under Article 5 of the Market Abuse Regulation, purchasing a total of 12,313 shares on Euronext Paris. The transactions were executed at a daily weighted...
Ipsen lifts 2026 guidance on strong H1 results and pipeline-boosting deals
Jul 30, 2026
Ipsen reported strong first-half 2026 results, with total sales rising 23.5% at constant exchange rates to €2.19bn and core operating income climbing 28.8% to €845m, lifting the core operating margin to 38.6%. Earnings and free cash fl...
Ipsen Strengthens Board with Appointment of Governance Expert Catherine Bradley
Jul 29, 2026
Ipsen has appointed Catherine Bradley as an independent director to its Board, succeeding Ms Witts following the May 2026 shareholders’ meeting. Bradley brings more than three decades of investment banking and international markets experienc...
Ipsen Reports Share Buybacks Totaling 13,930 Shares Over Late July
Jul 27, 2026
Ipsen disclosed aggregated data on transactions in its own shares carried out between 20 and 24 July 2026 on European markets. Over the period, the company repurchased a total of 13,930 shares of its FR0010259150 stock at a daily weighted average ...
Ipsen’s Bylvay misses Phase III goal in biliary atresia, limiting expansion bid
Jul 24, 2026
Ipsen reported that its Phase III BOLD trial of Bylvay (odevixibat) in infants with biliary atresia who had undergone Kasai surgery failed to improve native liver survival versus placebo, underscoring the difficulty of treating this rare paediatri...
Ipsen Corrects June 2026 Voting Rights and Share Capital Disclosure
Jul 22, 2026
Ipsen has issued a corrective statement regarding its monthly disclosure of total shares and voting rights as of 30 June 2026, filed under French market regulations and in line with AMF requirements for Euronext Paris issuers. The company confirms...
Ipsen buys Memo Therapeutics to add first-in-class BK virus antibody
Jul 22, 2026
Ipsen has completed the acquisition of Memo Therapeutics AG, gaining control of potravitug, a first-in-class monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant patients. The drug has shown significant antiviral activit...
Ipsen’s corabotase shows prolonged effect and high satisfaction in phase II glabellar lines trial
May 17, 2026
Ipsen reported phase II data for its first‑in‑class recombinant neuro‑inhibitor corabotase in patients with moderate to severe glabellar lines, showing a rapid onset of action, superior peak effect to placebo and stronger wrinkle...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.